S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.84 (-11.52%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.84 (-11.52%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.84 (-11.52%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.23 (-1.20%)
MSFT   420.96 (-0.11%)
META   489.18 (-0.95%)
GOOGL   150.88 (+0.01%)
AMZN   180.63 (+0.44%)
TSLA   177.44 (-1.33%)
NVDA   908.62 (+0.68%)
NIO   4.70 (+0.64%)
AMD   181.47 (+1.05%)
BABA   72.30 (+0.99%)
T   17.61 (+0.34%)
F   13.22 (+1.23%)
MU   118.98 (-0.13%)
CGC   8.91 (-6.70%)
GE   177.09 (-1.68%)
DIS   122.56 (+1.31%)
AMC   3.84 (-11.52%)
PFE   27.87 (+0.32%)
PYPL   66.77 (+0.30%)
XOM   115.34 (+0.32%)
NASDAQ:NARI

Inari Medical (NARI) Stock Price, News & Analysis

$48.17
+0.77 (+1.62%)
(As of 09:47 AM ET)
Today's Range
$47.25
$48.17
50-Day Range
$40.65
$59.03
52-Week Range
$39.90
$71.85
Volume
38,293 shs
Average Volume
994,491 shs
Market Capitalization
$2.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.71

Inari Medical MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
55.5% Upside
$73.71 Price Target
Short Interest
Healthy
7.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of Inari Medical in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$1.65 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.39) to $0.37 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.25 out of 5 stars

Medical Sector

345th out of 939 stocks

Surgical & Medical Instruments Industry

45th out of 99 stocks

NARI stock logo

About Inari Medical Stock (NASDAQ:NARI)

Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.

NARI Stock Price History

NARI Stock News Headlines

the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Inari Medical Shares Gain After Index Move
Forecasting The Future: 7 Analyst Projections For Inari Medical
$25,000 into $109,616 in two months?
Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…
NARI Apr 2024 65.000 call
Inari Medical CFO sells shares worth over $250k
See More Headlines
Receive NARI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inari Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:NARI
Fax
N/A
Employees
1,300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$73.71
High Stock Price Target
$100.00
Low Stock Price Target
$52.00
Potential Upside/Downside
+55.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-1,640,000.00
Pretax Margin
0.86%

Debt

Sales & Book Value

Annual Sales
$493.63 million
Cash Flow
$0.09 per share
Book Value
$8.07 per share

Miscellaneous

Free Float
51,817,000
Market Cap
$2.75 billion
Optionable
Optionable
Beta
0.84
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives


NARI Stock Analysis - Frequently Asked Questions

Should I buy or sell Inari Medical stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inari Medical in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NARI shares.
View NARI analyst ratings
or view top-rated stocks.

What is Inari Medical's stock price target for 2024?

6 Wall Street analysts have issued 1 year price targets for Inari Medical's stock. Their NARI share price targets range from $52.00 to $100.00. On average, they expect the company's stock price to reach $73.71 in the next year. This suggests a possible upside of 55.5% from the stock's current price.
View analysts price targets for NARI
or view top-rated stocks among Wall Street analysts.

How have NARI shares performed in 2024?

Inari Medical's stock was trading at $64.92 at the start of the year. Since then, NARI shares have decreased by 27.0% and is now trading at $47.40.
View the best growth stocks for 2024 here
.

Are investors shorting Inari Medical?

Inari Medical saw a decline in short interest during the month of March. As of March 15th, there was short interest totaling 3,580,000 shares, a decline of 29.1% from the February 29th total of 5,050,000 shares. Based on an average daily trading volume, of 946,700 shares, the short-interest ratio is currently 3.8 days. Currently, 7.2% of the company's shares are short sold.
View Inari Medical's Short Interest
.

When is Inari Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our NARI earnings forecast
.

How were Inari Medical's earnings last quarter?

Inari Medical, Inc. (NASDAQ:NARI) released its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by $0.09. The firm had revenue of $132.10 million for the quarter, compared to the consensus estimate of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive trailing twelve-month return on equity of 1.23%. The company's revenue was up 22.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.11) EPS.

What guidance has Inari Medical issued on next quarter's earnings?

Inari Medical updated its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $580.0 million-$595.0 million, compared to the consensus revenue estimate of $588.3 million.

What other stocks do shareholders of Inari Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Inari Medical investors own include NVIDIA (NVDA), Home Depot (HD), CVS Health (CVS), QUALCOMM (QCOM), Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Procter & Gamble (PG) and Bristol-Myers Squibb (BMY).

When did Inari Medical IPO?

Inari Medical (NARI) raised $110 million in an IPO on Friday, May 22nd 2020. The company issued 7,300,000 shares at a price of $14.00-$16.00 per share. BofA Securities and Morgan Stanley acted as the underwriters for the IPO and Canaccord Genuity and Wells Fargo Securities were co-managers.

Who are Inari Medical's major shareholders?

Inari Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (8.75%), Vanguard Group Inc. (8.69%), Wellington Management Group LLP (7.87%), Franklin Resources Inc. (4.91%), Brown Advisory Inc. (2.96%) and Voya Investment Management LLC (1.34%). Insiders that own company stock include Andrew Hykes, Ansbert Gadicke, Donald B Milder, Mitch C Hill, Mitch C Hill, Stanley Tang, Thomas Tu and William Hoffman.
View institutional ownership trends
.

How do I buy shares of Inari Medical?

Shares of NARI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NARI) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners